Press release | Research

MoniCardi begins collaboration with Ambiq using next-generation microchips

Published on 12.11.2025

Tampere University

Nainen katsoo älykellon lukemia selin kuvaajaan taustalla auringonlasku..

Photo: AdobeStock

MoniCardi, a newly established spin-off from Tampere University, has published a joint report with US-based Ambiq, demonstrating the compatibility of MoniCardi’s cardiac monitoring technology with Ambiq’s advanced microchips. This collaboration paves the way for increasingly accessible and effective monitoring of personal well-being and cardiac health across a growing range of devices.

The jointly published whitepaper Ultra-Low-Power Biosignal Analytics for Next-Generation Wearables confirms that MoniCardi’s sophisticated cardiac analytics solutions are compatible with Ambiq’s high-performance Apollo510 System-on-Chip (SoC), which delivers exceptionally low power consumption through the Subthreshold Power Optimized Technology (SPOT®) platform. MoniCardi’s technology can be directly integrated into portable devices using these chips without the need for any modifications or testing. This enables the efficient, large-scale deployment of cardiac analytics across diverse environments worldwide, says Professor Esa Räsänen, CEO of MoniCardi and Professor at Tampere University.

MoniCardi’s partner network includes stakeholders from both the consumer and healthcare sectors. The company’s analytics solutions have already been commercialised, for example, in Suunto’s ZoneSense technology launched in the autumn of 2024.

“This collaboration with MoniCardi exemplifies how Ambiq’s ultra-low power edge AI solutions are enabling meaningful innovations in health technology,” says Scott Hanson, Founder and CTO of Ambiq. “By combining MoniCardi’s advanced analytics with our Apollo510 platform, we’re making it possible to analyze complex physiological data efficiently and continuously — right on the device.”

“Collaboration with Ambiq marks a significant milestone for MoniCardi. Ambiq’s cutting-edge SPOT platform allows for precise and energy-efficient cardiac analysis on virtually any device. This enables us, in partnership with device manufacturers, to seamlessly integrate innovative heart rate variability monitoring into people’s daily lives,” adds Esa Räsänen.

According to Petri Räsänen, Head of Business Tampere’s Chips from Tampere programme, the collaboration between MoniCardi and Ambiq will further strengthen the semiconductor ecosystem in Tampere and highlight its diversity.

“The innovative application of chip technologies across sectors holds the potential to address real-world challenges faced by individuals and society at large,” he notes.

MoniCardi was founded in April 2024 as a spin-off from Tampere University, following a Research-to-Business project funded by Business Finland. In the spring of 2025, MoniCardi received a Silmu grant from the Instrumentarium Foundation and was selected for ESA BIC Finland, the European Space Agency’s Business Incubation Centre. The company applies advanced electrocardiographic (ECG) and heart rate variability (HRV) analytics, developed by physicists at Tampere University, for cardiac monitoring. These technologies are used, for instance, to accurately measure exercise intensity. MoniCardi’s ultimate goal is to enable the early detection of heart disease – and its research is already showing promising progress.

Ambiq, originally a spin-off from the University of Michigan, has become a global leader in the production of ultra low-power SoCs. Now headquarted in Austin, Texas, the company is recognised for its pioneering solutions that support edge AI-enabled applications across a wide range of devices. Ambiq has powered over 280 million devices to date. It was listed on the New York Stock Exchange in the summer of 2025 with a valuation exceeding $650 million.

The Ultra-Low-Power Biosignal Analytics for Next-Generation Wearables whitepaper can be read here.